Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/third-line-treatment-for-overactive-bladder-should-mirabegron-be-tried-RpPh1ayPcs
References (18)
-
D. Tincello, RK Owen, MC Slack, K. Abrams (2013)
Validation of the Patient Global Impression scales for use in detrusor overactivity: secondary analysis of the RELAX studyBJOG: An International Journal of Obstetrics & Gynaecology, 120
-
A. Rojas, R. Monroy, M. Salazar (2011)
Reseña de "Updated systematic review and meta-analysis of the comparative data on colposuspensions, pubovaginal slings, and midurethral tapes in the surgical treatment of female stress urinary incontinence" de Novara G, Artibani W, Barber MD et al. -
J. Duckett, Maria Vella, G. Kavalakuntla, Maya Basu (2007)
Tolerability and efficacy of duloxetine in a nontrial situationBJOG: An International Journal of Obstetrics & Gynaecology, 114
-
(2013)
Onabotulinumtoxin A for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial -
C. Chapple, V. Dvořák, Pjotr Radziszewski, P. Kerrebroeck, J. Wyndaele, Brigitte Bosman, P. Boerrigter, T. Drogendijk, A. Ridder, Ingrid Putten-Slob, O. Yamaguchi (2013)
A phase II dose-ranging study of mirabegron in patients with overactive bladderInternational Urogynecology Journal, 24
-
V. Khullar, G. Amarenco, J. Angulo, J. Cambronero, K. Høye, I. Milsom, P. Radziszewski, T. Rechberger, P. Boerrigter, T. Drogendijk, M. Wooning, C. Chapple (2013)
Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.European urology, 63 2
-
C. Chapple, V. Khullar, Z. Gabriel, D. Muston, C. Bitoun, D. Weinstein (2008)
The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis.European urology, 54 3
-
C. Chapple, L. Cardozo, V. Nitti, E. Siddiqui, M. Michel (2014)
Mirabegron in overactive bladder: A review of efficacy, safety, and tolerabilityNeurourology and Urodynamics, 33
-
V. Khullar, C. Chapple, Z. Gabriel, J. Dooley (2006)
The effects of antimuscarinics on health-related quality of life in overactive bladder: a systematic review and meta-analysis.Urology, 68 2 Suppl
-
(2013)
Overactive bladder—mirabegron (T290) -
V. Nitti, S. Auerbach, N. Martin, A. Calhoun, Misun Lee, S. Herschorn (2013)
Results of a randomized phase III trial of mirabegron in patients with overactive bladder.The Journal of urology, 189 4
-
R. Caremel, Oleg Loutochin, J. Corcos (2014)
What do we know and not know about mirabegron, a novel β3 agonist, in the treatment of overactive bladder?International Urogynecology Journal, 25
-
V. Nitti, S. Herschorn, S. Auerbach, M. Ayers, Misun Lee, N. Martin (2011)
885 THE EFFICACY AND SAFETY OF MIRABEGRON IN PATIENTS WITH OVERACTIVE BLADDER SYNDROME – RESULTS FROM A NORTH-AMERICAN PHASE III TRIALEuropean Urology Supplements, 10
-
G. Novara, W. Artibani, M. Barber, C. Chapple, E. Costantini, V. Ficarra, P. Hilton, C. Nilsson, D. Waltregny (2010)
Updated systematic review and meta-analysis of the comparative data on colposuspensions, pubovaginal slings, and midurethral tapes in the surgical treatment of female stress urinary incontinence.European urology, 58 2
-
K. Andersson (2013)
New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinATherapeutics and Clinical Risk Management, 9
-
A. Sicras-Mainar, J. Rejas, R. Navarro-artieda, A. Aguado-Jodar, A. Ruíz-Torrejón, J. Ibáñez-Nolla, M. Kvasz (2013)
Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in SpainBMC Urology, 13
-
C. Chapple, G. Amarenco, M. Aramburu, K. Everaert, J. Liehne, M. Lucas, V. Vik, A. Ridder, R. Snijder, O. Yamaguchi (2013)
A proof‐of‐concept study: Mirabegron, a new therapy for overactive bladderNeurourology and Urodynamics, 32
-
C. Dowson, J. Watkins, M. Khan, P. Dasgupta, A. Sahai (2012)
Repeated botulinum toxin type A injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates.European urology, 61 4
- Publisher
- Springer Journals
- Copyright
- Copyright © 2014 by The International Urogynecological Association
- Subject
- Medicine & Public Health; Gynecology; Urology
- ISSN
- 0937-3462
- eISSN
- 1433-3023
- DOI
- 10.1007/s00192-014-2462-2
- pmid
- 25030325
- Publisher site
- See Article on Publisher Site
Abstract
Int Urogynecol J (2015) 26:367–372 DOI 10.1007/s00192-014-2462-2 ORIGINAL ARTICLE Third-line treatment for overactive bladder: should mirabegron be tried before intravesical botulinum toxin A therapy? Aswini Balachandran & Natasha Curtiss & Maya Basu & Jonathan Duckett Received: 20 March 2014 /Accepted: 19 June 2014 /Published online: 17 July 2014 The International Urogynecological Association 2014 Abstract study supports mirabegron use as a third-line treatment for Introduction and hypothesis Mirabegron is a new beta 3 overactive bladder. agonist for the treatment of overactive bladder (OAB). . . Although there are extensive data from randomised con- Keywords Antimuscarinics Botulinum toxin A Detrusor . . . trolled trials, there is little real world evidence about its overactivity Mirabegron Overactive bladder Urinary effectiveness and side effects. We conducted a prospec- incontinence tive cohort study to evaluate the effectiveness of mirabegron as third-line treatment in patients with re- fractory OAB who did not benefit from antimuscarinic Introduction therapy and bladder drill. Methods The study was a prospective consecutive cohort Overactive bladder (OAB) affects 10–20 % of the adult pop- of 67 women treated with mirabegron 50 mg. All the ulation and its prevalence increases with age [1]. OAB has a patients had symptoms of urgency with
Journal
International Urogynecology Journal – Springer Journals
Published: Jul 17, 2014